title: [Follow-up of urothelial carcinoma: Review of the Cancer Committee of the French Association of Urology].
abstract: BACKGROUND
  Cancer Committee of the French Association of Urology (CCAFU) conducted a literature review concerning the follow-up of urothelial carcinomas and provides recommendations for monitoring.
  
  
  METHODS
  A bibliographic research in French and English using PubMed was carried out from 1990 to 2014 using the keywords "urothelial carcinoma", "follow-up", "prognosis", and "recurrence".
  
  
  RESULTS
  Rhythm and tools of follow-up (cytology, endoscopy, CT-urography) for non muscle invasive bladder cancer (NMIBC) have to be adjusted to the recurrence and progression risk defined by the EORTC tables. After radical treatment of muscle invasive bladder cancer (MIBC), follow-up is based on endoscopy, cytology and CT-urography. Monitoring of the urethra must be adapted to the recurrence factors and continued for at least 5 years. The monitoring of upper tract should be continued for life. In case of conservative treatment for MIBC, early endoscopy and imaging reassessment is required. After radical treatment of upper urinary tract tumour (UTUC), cystoscopy and cytology are essential because of the frequency of bladder recurrence in the first three years. Conservative management of UTUC requires strict monitoring including flexible ureteroscopy.
  
  
  CONCLUSIONS
  Oncologic follow-up of urothelial carcinomas is adapted according to tumour stage and grade, location and treatment modality thus defining the risk of recurrence over time.
authors.affiliation: Service d'urologie, hôpital privé de la Louvière, générale de santé, 59000 Lille, France. Electronic address: docpierrecolin@gmail.com.
authors.forename: P
authors.initials: P
authors.lastname: Colin
authors.affiliation: Service d'urologie, université de Versailles, hôpital Foch, 92150 Suresnes, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Neuzillet
authors.affiliation: Service d'urologie, université Paris-Sud, hôpital Bicêtre, 94270 Le-Kremlin-Bicêtre, France.
authors.forename: G
authors.initials: G
authors.lastname: Pignot
authors.affiliation: Service d'urologie, université Pierre-et-Marie-Curie, Paris 6, groupe hospitalier Pitié-Salpêtrière, 75013 Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Rouprêt
authors.affiliation: Service d'anatomopathologie, université Paris-Descartes, groupe hospitalier Pitié-Salpêtrière, 75013 Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Comperat
authors.affiliation: Service d'urologie, CHU de Reims, 51000 Reims, France.
authors.forename: S
authors.initials: S
authors.lastname: Larré
authors.affiliation: Service de radiologie et échographie, université de Strasbourg, Nouvel hôpital civil, 67000 Strasbourg, France.
authors.forename: C
authors.initials: C
authors.lastname: Roy
authors.affiliation: Département d'urologie, institut Arnault-Tzanck, 06700 Saint-Laurent-du-Var, France.
authors.forename: H
authors.initials: H
authors.lastname: Quintens
authors.affiliation: Service d'oncologie médicale, CHU de Nîmes, 30000 Nîmes, France.
authors.forename: N
authors.initials: N
authors.lastname: Houedé
authors.affiliation: Département d'urologie, université Paul-Sabatier, hôpital Rangueil, 31000 Toulouse, France.
authors.forename: M
authors.initials: M
authors.lastname: Soulié
authors.affiliation: Service d'urologie, université de Rouen, hôpital Charles-Nicolle, 76000 Rouen, France.
authors.forename: C
authors.initials: C
authors.lastname: Pfister
mesh_terms: D002277:Carcinoma / Q000473:pathology*; D003266:Continuity of Patient Care; D003952:Diagnostic Imaging; D005602:France; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D014571:Urologic Neoplasms / Q000473:pathology*; D019459:Urothelium / Q000473:pathology*
keywords: Carcinome urothélial; Follow-up; Prognosis; Pronostic; Recurrence; Récidive; Suivi; Urothelial carcinoma